In the last trading session, 1.5 million Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares changed hands as the company’s beta touched 1.17. With the company’s per share price at $9.61 changed hands at $0.91 or 10.46% during last session, the market valuation stood at $581.80M. DNA’s last price was a discount, traded about -682.52% off its 52-week high of $75.20. The share price had its 52-week low at $5.26, which suggests the last value was 45.27% up since then. When we look at Ginkgo Bioworks Holdings Inc’s average trading volume, we note the 10-day average is 1.23 million shares, with the 3-month average coming to 1.29 million.
Analysts gave the Ginkgo Bioworks Holdings Inc (DNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.83. If we narrow down to specifics, the data shows that 2 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended DNA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Instantly DNA was in green as seen at the end of in last trading. With action 33.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -85.78%, with the 5-day performance at 33.84% in the green. However, in the 30-day time frame, Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 26.12% up. Looking at the short shares, we see there were 7.32 million shares sold at short interest cover period of 6.57 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6.5, meaning bulls need a downside of -47.85% from its current market value. According to analyst projections, DNA’s forecast low is 4.35 with 12 as the target high. To hit the forecast high, the stock’s price needs a -24.87% plunge from its current level, while the stock would need to tank 54.73% for it to hit the projected low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Data shows that the Ginkgo Bioworks Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -55.64% over the past 6 months, a 35.77% in annual growth rate that is considerably higher than the industry average of 17.70%.
The 2024 estimates are for Ginkgo Bioworks Holdings Inc earnings to increase by 45.22%, but the outlook for the next 5-year period is at 31.20% per year.
DNA Dividends
Ginkgo Bioworks Holdings Inc is expected to release its next quarterly earnings report in January.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.16% of Ginkgo Bioworks Holdings Inc shares while 68.53% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 73.03%. There are 68.53% institutions holding the Ginkgo Bioworks Holdings Inc stock share, with VIKING GLOBAL INVESTORS LP the top institutional holder. As of 2024-06-30, the company held 7.1383% of the shares, roughly 143.09 million DNA shares worth $47.83 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.9327% or 138.96 million shares worth $46.46 million as of 2024-06-30.
